The Claim

The dual-threshold strategy (≤0.00370 negative, ≥0.00738 positive) for the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio reduces indeterminate results to 19.6% in adults with cognitive complaints and enables a blood-first diagnostic pathway that eliminates the need for confirmatory CSF or PET testing in 75.8% of cases.

Source: Multicenter validation of plasma p‐tau217/ amyloid beta 1‐42 ratio in symptomatic Alzheimer's disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
44score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

A specific blood test using the Lumipulse G pTau217/β-Amyloid 1-42 ratio with defined thresholds reduces ambiguous results to 19.6% in adults with cognitive complaints and removes the need for spinal fluid or brain imaging tests in 75.8% of cases.

See the scientific wording

The dual-threshold strategy (≤0.00370 negative, ≥0.00738 positive) for the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio reduces indeterminate results to 19.6% in adults with cognitive complaints, enabling a blood-first diagnostic pathway that could eliminate the need for confirmatory CSF or PET testing in 75.8% of cases.

Why this might work

When Alzheimer's disease develops, the brain produces excess abnormal tau protein and amyloid plaques. These proteins leak into the blood in predictable amounts. A blood test measures the ratio of these two proteins. If the ratio is very low, the brain does not have Alzheimer's changes. If the ratio is very high, the brain has clear Alzheimer's changes. This allows doctors to say yes or no without needing a spinal tap or brain scan.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Multicenter validation of plasma p‐tau217/ amyloid beta 1‐42 ratio in symptomatic Alzheimer's disease

    This blood test uses two specific numbers to tell if someone likely has Alzheimer’s brain changes. The study found that about 1 in 5 people got an unclear result, meaning 4 out of 5 got a clear answer — so doctors could avoid spinal taps or brain scans for most people.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.